On August 6, 2025, Prothena announced that its partner Novo Nordisk will advance coramitug, a potential first-in-class amyloid depleter antibody, into Phase 3 development for ATTR amyloidosis with ...

Citizens JMP analyst Jason Butler reiterated a Buy rating on Prothena today and set a price target of $29.00. The company’s shares closed yesterday at $6.94. Elevate Your Invest ...

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

Shares of Prothena Corporation plc (PRTA) soared on Wednesday after Danish drugmaker Novo Nordisk (NVO) said that it expects ...

Shares of Prothena climbed after Novo Nordisk said during its second-quarter earnings call that it expects to advance a treatment for amyloidosis it bought from Prothena in 2021. The Dublin company's ...

Prothena announced that Novo Nordisk communicated that they expect to advance coramitug into a Phase 3 program for ATTR-CM in 2025.

In the assessment of 12-month price targets, analysts unveil insights for Prothena Corp, presenting an average target of $34.67, a high estimate of $81.00, and a low estimate of $4.00. Observing a ...

Prothena today reported financial results for the second quarter and first six months of 2025 and provided business highlights.

Return on Equity (ROE): Prothena Corp's ROE falls below industry averages, indicating challenges in efficiently using equity ...

The latest update is out from Prothena ( (PRTA) ).

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in ...

No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic alpha-synuclein ...